|
🐜
|
Boceprevir for previously treated chronic HCV genotype 1 infection.
14 auth.
B. Bacon,
S. Gordon,
E. Lawitz,
P. Marcellin,
J. Vierling,
S. Zeuzem,
F. Poordad,
Z. Goodman,
H. Sings,
N. Boparai,
...
M. Burroughs,
C. Brass,
J. Albrecht,
R. Esteban
|
10 |
2011 |
10
🐜
|
|
🐢
|
Diagnosis and management of autoimmune hepatitis
7 auth.
M. Manns,
A. Czaja,
J. Gorham,
E. Krawitt,
G. Mieli-Vergani,
D. Vergani,
...
J. Vierling
|
9 |
2010 |
9
🐢
|
|
🐜
|
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
19 auth.
P. Kwo,
E. Lawitz,
J. McCone,
E. Schiff,
J. Vierling,
D. Pound,
Mitchell N. Davis,
J. Galati,
S. Gordon,
N. Ravendhran,
...
L. Rossaro,
F. Anderson,
I. Jacobson,
R. Rubin,
K. Koury,
L. Pedicone,
C. Brass,
E. Chaudhri,
J. Albrecht
|
9 |
2010 |
9
🐜
|
|
🐜
|
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
10 auth.
C. Mack,
D. Adams,
D. Assis,
N. Kerkar,
M. Manns,
M. Mayo,
...
J. Vierling,
Mouaz Alsawas,
M. Murad,
A. Czaja
|
9 |
2019 |
9
🐜
|
|
🐜
|
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
33 auth.
H. Ford,
M. Bourliere,
S. Gordon,
S. Flamm,
C. Cooper,
A. Ramji,
M. Tong,
N. Ravendhran,
J. Vierling,
T. Tran,
S. Pianko,
M. Bansal,
V. Ledinghen,
R. Hyland,
L. Stamm,
...
H. Dvory‐Sobol,
E. Svarovskaia,
Jie Zhang,
K. C. Huang,
G. Subramanian,
D. Brainard,
J. Mchutchison,
E. Verna,
P. Buggisch,
C. Landis,
Z. Younes,
M. Curry,
S. Strasser,
E. Schiff,
K. Reddy,
M. Manns,
K. Kowdley,
S. Zeuzem
|
9 |
2017 |
9
🐜
|
|
🐢
|
Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview‐based study of 1032 patients
9 auth.
M. Gershwin,
C. Selmi,
H. Worman,
E. Gold,
M. Watnik,
J. Utts,
...
K. Lindor,
M. Kaplan,
J. Vierling
|
9 |
2005 |
9
🐢
|
|
🐜
|
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
10 auth.
F. Poordad,
E. Schiff,
J. Vierling,
C. Landis,
R. Fontana,
Rong Yang,
...
F. Mcphee,
E. Hughes,
S. Noviello,
E. Swenson
|
8 |
2016 |
8
🐜
|
|
🐜
|
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
38 auth.
S. Zeuzem,
G. Foster,
Stanley Wang,
A. Asatryan,
E. Gane,
J. Feld,
T. Asselah,
M. Bourliere,
P. Ruane,
H. Wedemeyer,
S. Pol,
R. Flisiak,
F. Poordad,
W. Chuang,
C. Stedman,
...
S. Flamm,
P. Kwo,
G. Dore,
Gladys Sepúlveda-Arzola,
S. Roberts,
R. Soto‐malave,
K. Kaita,
M. Puoti,
J. Vierling,
E. Tam,
H. Vargas,
R. Bruck,
F. Fuster,
S. Paik,
F. Felizarta,
J. Kort,
B. Fu,
Ran Liu,
T. Ng,
T. Pilot-matias,
Chih‐Wei Lin,
R. Trinh,
F. Mensa
|
8 |
2018 |
8
🐜
|
|
🐜
|
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
20 auth.
K. Kowdley,
E. Lawitz,
I. Crespo,
T. Hassanein,
Mitchell N. Davis,
M. Demicco,
D. Bernstein,
N. Afdhal,
J. Vierling,
S. Gordon,
...
Jane Anderson,
R. Hyland,
H. Dvory‐Sobol,
D. An,
R. Hindes,
E. Albanis,
W. Symonds,
M. Berrey,
D. Nelson,
I. Jacobson
|
8 |
2013 |
8
🐜
|
|
🐜
|
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
7 auth.
M. Ghany,
B. Ayola,
F. Villamil,
R. Gish,
S. Rojter,
J. Vierling,
...
A. Lok
|
8 |
1998 |
8
🐜
|
|
🐜
|
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.
10 auth.
R. Fontana,
H. Hann,
R. Perrillo,
J. Vierling,
T. Wright,
J. Rakela,
...
G. Anschuetz,
Randy L. Davis,
S. Gardner,
N. Brown
|
8 |
2002 |
8
🐜
|
|
🐜
|
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
18 auth.
P. Kwo,
E. Gane,
C. Peng,
Brian L. Pearlman,
J. Vierling,
L. Serfaty,
M. Buti,
S. Shafran,
P. Stryszak,
Li Lin,
...
J. Gress,
Stuart Black,
F. Dutko,
M. Robertson,
J. Wahl,
L. Lupinacci,
E. Barr,
B. Haber
|
8 |
2017 |
8
🐜
|
